Home / Business and Economy / Lilly's Q2 Earnings Surge, Fueled by Mounjaro and Zepbound Sales
Lilly's Q2 Earnings Surge, Fueled by Mounjaro and Zepbound Sales
6 Aug
Summary
- Q2 revenue up 30% YoY to $14.7B, beating estimates
- Adjusted EPS rises 4% YoY to $5.60, following strong Q1
- Investors focus on sustainability of Mounjaro and Zepbound demand
Eli Lilly & Co. has reported its Q2 2025 results, which have exceeded analysts' expectations. The company's revenue for the quarter is approximately $14.7 billion, up around 30% year-over-year, while its adjusted earnings per share (EPS) have risen roughly 4% to $5.60.
This follows a strong Q1 performance, where Lilly's adjusted EPS was $3.34 on revenue of $12.73 billion, beating estimates by a modest margin. The company's shares have declined slightly year-to-date, underperforming some of its peers despite the strong momentum from its obesity and diabetes drug sales.
Investors will be focused on the sustainability of the strong demand for Lilly's Mounjaro and Zepbound drugs. After a robust Q1, the market will be looking for confirmation that this momentum has continued into Q2. Additionally, updates on the company's manufacturing capacity and how it is managing its supply chain to meet this demand will be closely watched.
Advertisement
Advertisement
Beyond the leading drugs, attention will also be on the performance of Lilly's other key growth drivers, such as the cancer drug Verzenio. Updates on the company's broader pipeline, particularly its oral GLP-1 candidate orforglipron, will be important for assessing its long-term growth prospects.
Lilly's management has updated its guidance for the full year 2025, now projecting adjusted EPS in the range of $20.78 to $22.28, down from previous forecasts due to a one-time cost associated with the Scorpion Therapeutics acquisition. Investors will be listening for commentary on whether the full-year revenue and EPS targets still reflect the company's operational momentum.
